A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy

Cancer

Volumn 117, Issue 10, 2011, Pages 2050-2057

  Jeung, Hei Cheul ^a,b   Rha, Sun Young ^a,b   Im, Chong Kun ^a   Shin, Sang Joon ^a   Ahn, Joong Bae ^a   Yang, Woo Ick ^b   Roh, Jae Kyung ^a,b   Noh, Sung Hoon ^b   Chung, Hyun Cheol ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

biomarker; chemotherapy; clinical trial; docetaxel; gastric cancer; SPARC

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; OSTEONECTIN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHEMATOLOGICAL TOXICITY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEONECTIN; OXONIC ACID; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR;

EID: 79955512443     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25729     Document Type: Article

References (31)

1. Roth AD, Maibach R, Martinelli G, et al. Docetaxel(Taxotere)- cisplatin(TC): an effective drug combination in gastric carcinoma. Ann Oncol. 2000; 11: 301-306. (Pubitemid 30214667)
2. Kim KH, Jeung KJ, Kim HJ, et al. Phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with recurrent or metastatic gastric cancer. Cancer Res Treat. 2007; 39: 49-53.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006; 24: 4991-4997. (Pubitemid 46631401)
4. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007; 25: 3217-3223. (Pubitemid 47325604)
5. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin vs S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215-221.
6. Imamura H, Ilishi H, Tsuburaya A, et al. Randomized phase III study of irintoecan plus S-1 (IRIS) vs S-1 alone as fist-line treatment for advanced gastric cancer (GC3031/TOP-002). Presented at: 2008 ASCO Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 5.
7. Kang HJ, Cho SH, Oh SJ, et al. Phase II study of S-1 and irinotecan combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05-02. Asia Pac J Clin Oncol. 2009; 5: 46-54.
8. Wada Y, Yoshida K, Suzuki T, et al. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006; 119: 783-791. (Pubitemid 44055889)
9. Yamaguchi K, Simamura T, Hyodo I, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer. 2006; 94: 1803-1808. (Pubitemid 43884569)
10. Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006; 12: 3402-3407.
11. Park SR, Kim HG, Kim CG, et al. Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br J Cancer. 2008; 98: 1305-1311. (Pubitemid 351543578)
12. Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S., Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer. 2004; 91: 1924-1930. (Pubitemid 40065522)
13. Zhao ZS, Wang YY, Chu YQ, Ye ZY, Tao HQ., SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2010; 16: 260-268.
14. Phelps SLB, Carbon J, Miller A, et al. Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. Am J Obstet Gynecol. 2009; 200: 180. e1-7.
15. Huynh MH, Sodek K, Lee H, et al. Interaction between SPARC and tubulin in Xenopus. Cell Tissue Res. 2004; 317: 313-317. (Pubitemid 39222950)
16. Jeung HC, Rha SY, Kim HK, et al. Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist. 2007; 12: 543-554.
17. Burstein DE, Idrees MT, Li G, Wu M, Kalir T., Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma. Ann Diagn Pathol. 2008; 12: 85-89. (Pubitemid 351312907)
18. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM., Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. 2004; 45; 47-54. (Pubitemid 38969561)
19. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005; 23: 5660-5667.
20. Milward MJ, Zalcberg J, Bishop JF, et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol. 1997; 15: 750-758. (Pubitemid 27074245)
21. Pronk LC, Schellens JH, Planting AS, et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol. 1997; 15: 1071-1079. (Pubitemid 27106291)
22. Takahashi I, Emi Y, Kakeji Y, Uchida J, Fukuyama M, Maehara Y., Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclincial study using gastric cancer xenograft. Oncology. 2005; 68: 130-137. (Pubitemid 41158968)
23. Maeda S, Sugiura T, Saikawa Y, et al. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci. 2004; 95: 679-684.
24. Chun JH, Kim HK, Lee JS, et al, Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol. 2005; 28: 188-194. (Pubitemid 40514433)
25. Lo SS, Khorana AA, Javle M, et al. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 2010; 78; 125-129.
26. Childress J, Lokich J., Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol. 2003; 26: 435-436. (Pubitemid 37248257)
27. Wilson D, Hiller J, Geh JI., Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol. 2005; 17: 81-90. (Pubitemid 40309884)
28. Van Cutsem E, Kang YK, Chung HC, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Proc Am Soc Clin Oncol. 2009; 27: P18s.
29. Bang YJ, Chung HC, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. Proc Am Soc Clin Oncol. 2009; 27: P15s.
30. Weaver MS, Workman G, Sage EH., The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin β1 and activation of integrin-linked kinase. J Biol Chem. 2008; 283: 22826-22837.
31. Fujii M., Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol. 2008; 13: 201-205. (Pubitemid 351871896)